New information regarding RhuDex(TM)
(Thomson Reuters ONE) - Lund, Sweden, August 7, 2009 - Active Biotech AB's (NASDAQ OMXNordic: ACTI) collaboration partner MediGene AG (Frankfurt: MDG,Prime Standard, TecDAX) today announce information regarding thecandidate drug RhuDex(TM) for the treatment of rheumatoid arthritis.In cooperation with the British drug regulatory authority MHRA(Medicines and Healthcare Products Regulatory Agency), MediGene hasconducted a series of in-vitro studies to rule out any potentialdetrimental interaction between RhuDex(TM) and arteriosclerotic bloodvessels.The results are now submitted to the regulatory authority forappraisal. Upon approval of the authorities, clinical development ofthe drug candidate may be resumed before the end of this year.To read the complete press release, please see www.medigene.com.Lund, August 7, 2009Active Biotech AB (publ)Tomas LeandersonPresident and CEOFor further information, please contact:Göran Forsberg, VP Investor Relations & Business DevelopmentTel: +46 (0) 46 19 11 54E-mail: goran.forsberg(at)activebiotech.comNotes to editorsAbout RhuDex(TM)RhuDex is a novel, orally available compound for the treatment ofrheumatoid arthritis, originating from Active Biotech's patented CD80antagonists, out-licensed to MediGene AG. RhuDex is being developedas a disease-modifying drug for the treatment of rheumatic diseases.About Active BiotechActive Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnologycompany with focus on autoimmune/inflammatory diseases and cancer.Projects in pivotal phase are laquinimod, an orally administeredsmall molecule with unique immunomodulatory properties for thetreatment of multiple sclerosis, as well as ANYARA for use in cancertargeted therapy, primarily of renal cancer. Further key projects inclinical development comprise the three orally administered compoundsTASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Pleasevisit www.activebiotech.com for more information.Active Biotech ABPO Box 724, SE-220 07 LundSwedenTel: +46 (0)46-19 20 00Fax: +46 (0)46-19 11 00Active Biotech is required under the Securities Markets Act to makethe information in this press release public. The information wassubmitted for publication at 08:30 a.m. CET on August 7, 2009.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 07.08.2009 - 08:30 Uhr
Sprache: Deutsch
News-ID 4475
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 507 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"New information regarding RhuDex(TM)"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
